IPA and RIBOPRO partner to advance mRNA-driven antibody discovery
IPA and RIBOPRO have announced a strategic collaboration to revolutionize therapeutic antibody discovery. By integrating RIBOPRO’s advanced mRNA and lipid nanoparticle (LNP) technologies with IPA’s AI-driven antibody discovery platform, the partnership aims to enhance antigen expression and immune responses, accelerating the development of novel therapeutics. This alliance strengthens the potential for AI-powered precision medicine by optimizing antibody discovery workflows with innovative mRNA-based immunization strategies.
Read the full press release here.